Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure

Hypertension

Volumn 67, Issue 2, 2016, Pages 424-429

  Arnold, Amy C ^a   Okamoto, Luis E ^a   Gamboa, Alfredo ^a   Black, Bonnie K ^a   Raj, Satish R ^a   Elijovich, Fernando ^a   Robertson, David ^a   Shibao, Cyndya A ^a   Biaggioni, Italo ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; angiotensin; autonomic nervous system; blood pressure; hypertension

Indexed keywords

EPLERENONE; MINERALOCORTICOID RECEPTOR; PLACEBO; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MALE; NATRIURESIS; NOCTURIA; ORTHOSTATIC BLOOD PRESSURE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHY DRAGER SYNDROME; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PURE AUTONOMIC FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PURE AUTONOMIC FAILURE; SPIRONOLACTONE; SUPINE POSITION; TREATMENT OUTCOME;

EID: 84954362209     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06617     Document Type: Article

References (29)

1. Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res. 2008;18(suppl 1):2-7. doi: 10.1007/s10286-007-1004-0.
2. Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin. 2002;20:291-301, vii.
3. Milazzo V, Di Stefano C, Milan A, Ravera A, Sobrero G, Sabia L, Veglio F, Maule S. Cardiovascular complications in patients with autonomic failure. Clin Auton Res. 2015;25:133-140. doi: 10.1007/s10286-015-0275-0.
4. Baser SM, Brown RT, Curras MT, Baucom CE, Hooper DR, Polinsky RJ. Beta-receptor sensitivity in autonomic failure. Neurology. 1991;41:1107-1112.
5. Biaggioni I, Garcia F, Inagami T, Haile V. Hyporeninemic normoaldosteronism in severe autonomic failure. J Clin Endocrinol Metab. 1993;76:580-586. doi: 10.1210/jcem.76.3.7680352.
6. Gordon RD, Küchel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Invest. 1967;46:599-605. doi: 10.1172/JCI105561.
7. Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, Biaggioni I. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61:701-706. doi: 10.1161/HYPERTENSIONAHA.111.00377.
8. Barrett KV, McCurley AT, Jaffe IZ. Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol. 2013;40:902-909. doi: 10.1111/1440-1681.12125.
9. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010;52:393-400. doi: 10.1016/j.pcad.2009.12.003.
10. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-650. doi: 10.1161/01.RES.0000159937.05502.d1.
11. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6:125-126.
12. Low PA. Testing the autonomic nervous system. Semin Neurol. 2003;23:407-421. doi: 10.1055/s-2004-817725.
13. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220. doi: 10.1172/JCI113298.
14. Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004;17:217-220.
15. Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128.
16. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512-2518. doi: 10.1161/01.CIR.0000071081.35693.9A.
17. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
18. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J. 2007;54:359-370.
19. Wilcox CS, Aminoff MJ, Penn W. Basis of nocturnal polyuria in patients with autonomic failure. J Neurol Neurosurg Psychiatry. 1974;37:677-684.
20. Shavit L, Neykin D, Lifschitz M, Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligoanuric chronic hemodialysis patients-a pilot study. Clin Nephrol. 2011;76:388-395.
21. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
22. Fejes-Tóth G, Pearce D, Náray-Fejes-Tóth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA. 1998;95:2973-2978.
23. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76:834-839. doi: 10.1016/j.steroids.2011.02.015.
24. Gamboa A, Shibao C, Diedrich A, Paranjape SY, Farley G, Christman B, Raj SR, Robertson D, Biaggioni I. Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension. 2008;51:1531-1536. doi: 10.1161/HYPERTENSIONAHA.107.105171.
25. Okamoto LE, Gamboa A, Shibao CA, Arnold AC, Choi L, Black BK, Raj SR, Robertson D, Biaggioni I. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension. 2014;64:1241-1247. doi: 10.1161/HYPERTENSIONAHA.114.04116.
26. Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006;47:522-526. doi: 10.1161/01.HYP.0000199982.71858.11.
27. Reyes AJ, Leary WP, Crippa G, Maranhaõ MF, Hernández-Hernández R. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med. 2005;16:3-11. doi: 10.1016/j.ejim.2004.10.007.
28. Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34:273-284. doi: 10.1016/j.semnephrol. 2014.04.004.
29. Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710-2715.